Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jayaram S. Bharadwaj"'
Autor:
Inderjit Mehmi, Gajanan Bhat, Julio Antonio Peguero, Lee S. Schwartzberg, Zane Yang, Patrick Wayne Cobb, Shanta Chawla, Jayaram S. Bharadwaj, Osama Hlalah, Steven J. Hasal, Richy Agajanian, Alvaro Restrepo
Publikováno v:
The Oncologist
Background Eflapegrastim, a novel, long‐acting recombinant human granulocyte‐colony stimulating factor (rhG‐CSF), consists of a rhG‐CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Preclinical and phas
Autor:
Jayaram S. Bharadwaj, Julio Antonio Peguero, Inderjit Mehmi, Patrick Wayne Cobb, Francois Lebel, Shanta Chawla, Gajanan Bhat, Richy Agajanian, Lee S. Schwartzberg, Alvaro Restrepo, Osama Hlalah
Publikováno v:
Cancer Research. 80:P2-14
Background: Eflapegrastim (E) represents the first myeloid growth factor innovation in more than 15 years. A novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), E consists of a rhG-CSF analog conjugated to a human Ig
Autor:
Shanta Chawla, Manuel Modiano, Jayaram S. Bharadwaj, Jawad Francis, Hlalah Osama, Lee S. Schwartzberg, Nishan Tchekmedyian, Francois Lebel, Gajanan Bhat
Publikováno v:
Blood. 136:34-35
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Manuel Modiano, Shanta Chawla, Jayaram S. Bharadwaj, Jawad Francis, Lee S. Schwartzberg, Francois Lebel, Gajanan Bhat, Hlalah Osama, Nishan Tchekmedyian
Publikováno v:
Cancer Research. 81:OT-06
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Shanta Chawla, Inderjit Mehmi, Alvaro Restrepo, Jayaram S. Bharadwaj, Gajanan Bhat, Patrick Wayne Cobb, Osama Hlalah, Lee S. Schwartzberg
Publikováno v:
Journal of Clinical Oncology. 37:61-61
61 Background: Eflapegrastim (E) is a novel, long-acting GCSF comprised of recombinant human GCSF covalently linked to human IgG4 Fc fragment via a PEG linker (MW, 72 kDa). E showed increased potency vs pegfilgrastim (P) in preclinical and Phase I an
Autor:
Lee S. Schwartzberg, Gajanan Bhat, Jayaram S. Bharadwaj, Osama Hlalah, Alvaro Restrepo, Inderjit Mehmi, Shanta Chawla, Patrick Wayne Cobb
Publikováno v:
Journal of Clinical Oncology. 37:539-539
539 Background: Eflapegrastim (E) is a novel long-acting GCSF comprised of recombinant human GCSF covalently linked to human IgG4 Fc fragment via a PEG linker (MW, 72 kDa). E showed increased potency vs pegfilgrastim (P) in preclinical and Phase I an
Autor:
Julio Antonio Peguero, Richy Agajanian, Zandong Yang, Patrick Wayne Cobb, Inderjit Mehmi, Osama Hlalah, Alvaro Restrepo, Lee S. Schwartzberg, Jayaram S. Bharadwaj, Gajanan Bhat
Publikováno v:
Journal of Clinical Oncology. 36:e12513-e12513
e12513Background: Eflapegrastim is a novel investigational biologic comprised of recombinant human G-CSF covalently linked to the human immunoglobulin G4FC fragment using proprietary LAPSCOVERY™ te...
Publikováno v:
Clinical advances in hematologyoncology : HO. 2(7)
Publikováno v:
Journal of cutaneous pathology. 31(6)
Post-transplant lymphoproliferative disorder (PTLD) is a condition affecting immunosuppressed transplant patients and has a variety of clinical presentations. It is rarely found in the skin, and cases of PTLD in the skin are usually linked with lymph